Skip to main content
. 2022 Apr 12;11(8):2148. doi: 10.3390/jcm11082148

Figure 1.

Figure 1

The clinical development pipeline of therapies for transthyretin amyloid cardiomyopathy (ATTR-CM). * Approved by the American food and drug administration and the European medicine agency for the treatment of ATTR-polyneuropathy. Figure cartoons were created with Biorender.com (accessed on 11 March 2022).